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Abstract 
The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of 
schizophrenia,particularly with regards to auditory hallucinations. In this study, using in situ quantitative 
autoradiography in postmortem tissue, we investigated the binding of the [3H]ketanserin to 5-HT2A 
receptors and [3H] mesulergine to 5-HT2C receptors in the left STG of 8 male schizophrenic patients 
compared to 8 control subjects. A strong [3H]ketanserin binding was observed in the STG, however there 
was a very weak [3H] mesulergine binding in the STG. A significant decrease in binding of [3H]ketanserin 
was clearly observed in schizophrenia patients in comparison with control subjects. There were no 
significant correlations between 5-HT2A binding density and age, postmortem intervals, or brain pH. 
These results suggest that the alterations of the 5-HT2A receptors contribute to the pathophysiology of 
the STG in schizophrenia. Furthermore, there is a clear tendency for a positive correlation between 
5-HT2A and muscarinic M1 receptor bindings, and for negative correlations between 5-HT2A and GABAA 
receptor bindings and between muscarinic M1 and GABAA receptor bindings. This provides a possible 
mechanism of auditory hallucinations through interactions between 5-HT2A, acetylcholine muscarinic 
and GABA transmissions in the STG in schizophrenia. 
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Abstract: 
 
The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of 
schizophrenia, particularly with regards to auditory hallucinations. In this study, using in 
situ quantitative autoradiography in postmortem tissue, we investigated the binding of the 
[3H]ketanserin to 5-HT2A receptors and [
3H]mesulergine to 5-HT2C receptors in the left 
STG of 8 male schizophrenic patients compared to 8 control subjects. A strong 
[3H]ketanserin binding was observed in the STG, however there was a very weak 
[3H]mesulergine binding in the STG. A significant decrease in binding of [3H]ketanserin 
was clearly observed in schizophrenia patients in comparison with control subjects. There 
were no significant correlations between 5-HT2A binding density and age, postmortem 
intervals, or brain pH. These results suggest that the alterations of the 5-HT2A receptors 
contribute to the pathophysiology of the STG in schizophrenia. Furthermore, there is a 
clear tendency for a positive correlation between 5-HT2A and muscarinic M1 receptor 
bindings, and for negative correlations between 5-HT2A and GABAA receptor bindings 
and between muscarinic M1 and GABAA receptor bindings. This provides a possible 
mechanism of auditory hallucinations through interactions between 5-HT2A, acetylcholine 
muscarinic and GABA transmissions in the STG in schizophrenia. 
 
Key words: Schizophrenia; 5-HT2A receptor; GABA receptor; Muscarinic receptor; 
Superior temporal gyrus  
Abbreviations: PMI, postmortem intervals; STG, superior temporal gyrus; 5-HT, 
serotonin 2; cc, corpus callosum; IG, insular gyrus; lf, lateral fissure; MTG, 
medial temporal gyrus; sts, superior temporal sulcus; Th, thalamus. 
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1. Introduction 
There is strong evidence that serotonin 2 (5-HT2) receptors are involved in the 
neuropathology and treatment of schizophrenia. There is a clear association between 
polymorphism of the 5-HT2A receptor gene and schizophrenia (Abdolmaleky et al., 2004; 
Ott et al., 2005; Saiz et al., 2007). Postmortem studies have also shown that 5-HT2A 
receptor mRNA is reduced in the dorsolateral prefrontal and anterior cingulate cortices, 
hippocampus, and striatum in schizophrenia (Burnet et al., 1996; Lopez-Figueroa et al., 
2004). Recently Hurlemann and colleagues revealed that schizophrenia subjects at 
predromal or at-risk mental states have decreased 5HT2A receptor densities in the 
dorsolateral prefrontal and posterior insular cortices, amygdalae, hippocampus and 
striatum (Hurlemann et al., 2005; Hurlemann et al., 2008). Autoradiographic binding 
studies in postmortem tissue have also found a significant decrease in the density of 
[3H]ketanserin binding to the 5-HT2A receptor in the prefrontal and planum temporal 
cortices, as well as the hippocampus (Burnet et al., 1996; Dean and Hayes, 1996; Pralong 
et al., 2000; Scarr et al., 2004; Matsumoto et al., 2005). However, some controversial 
findings have also been reported. For example, a number of studies did not reveal the 
association between polymorphism of the 5-HT2A receptor gene and schizophrenia 
(Verga et al., 1997; Li et al., 2006). Some earlier PET scan studies did not find any 
abnormality of 5-HT2A receptor density in schizophrenia (Trichard et al., 1998; Verhoeff 
et al., 2000).  A recent PET study in neuroleptic-naïve first episode schizophrenia has 
found there was no changes in 5-HT2A receptor binding in the cortical regions, although 
an increase in the caudate nucleus was detected (Erritzoe et al., 2008). On the other hand, 
a postmortem study did not show any changes of [3H]ketanserin binding density in the 
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hippocampus, although it observed a binding decrease in the prefrontal cortex 
(Matsumoto et al., 2005).  
 
There is much less information available on the possible pathological roles of 5-HT2C in 
schizophrenia. Editing of 5-HT2C receptor RNA has been reported to be reduced in the 
frontal cortex (left Brodmann’s area 46) in schizophrenia, which indicates a potential 
alteration of this receptor (Sodhi et al., 2001). To date, no 5-HT2C receptor binding study 
has been performed on postmortem tissue. Therefore, further study is necessary to verify 
the pathological mechanisms of 5-HT2A and 5-HT2C receptors in schizophrenia, 
particularly to investigate whether alteration of 5-HT2A receptors occurs in other brain 
regions involved in the pathology of schizophrenia. 
 
The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of 
schizophrenia, particularly with regards to auditory hallucinations (Silbersweig et al., 
1995; Kim et al., 2003; Gaser et al., 2004). However, there are only a few studies on 5-
HT2 receptors in the STG in schizophrenia. By assessing the loudness dependence of 
auditory evoked potentials, it has been shown that dysfunction of 5-HT2 receptors may 
cause deficits of auditory processing in schizophrenia (Juckel et al., 2003). A significant 
decrease in 5-HT2A receptor mRNA expression has been found in the STG in 
schizophrenia (Burnet et al., 1996). It is also interesting that 5-HT2A and 5-HT2C 
receptors are known to be important target sites of hallucinogens like lysergic acid (LSD) 
(Nichols, 2004). Furthermore, 5-HT2A is the target of several atypical antipsychotics 
(such as clozapine and olanzapine) that have been proven to be effective in the treatment 
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of schizophrenia (Schmidt et al., 1995; Tyson et al., 2004). In this study, we have 
examined 5-HT2A (using [
3H]ketanserin) and 5-HT2C receptor (using [
3H]mesulergine) 
bindings in the STG of schizophrenic patients and control subjects using quantitative 
autoradiography. Combined with data from previous studies (Deng and Huang, 2005, 
2006), the relationships between 5-HT2A, muscarinic and GABAA receptors were also 
examined. 
 
2. Methods and Materials 
2.1 Subjects and preparation of postmortem brain tissue 
Postmortem brain tissue was obtained from the NSW Tissue Resource Centre (TRC), 
including 8 schizophrenic patients and 8 controls matched by age, gender (all males), 
race (all Caucasian Australian) and postmortem intervals (PMI). The diagnosis of 
schizophrenia was established after review of all available medical records by using the  
Diagnostic Instrument for Brain Studies (Keks et al., 1999). The diagnosis of 
schizophrenia was confirmed according to the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) (Sheedy et al., 2008). All schizophrenic subjects had a 
positive rating in auditory hallucinations, in which a positive rating was defined as 
experiencing auditory hallucinations twice per month. For control cases, medical records 
were reviewed to exclude any history of major psychiatric disorders and, if necessary, to 
exclude possible psychopathology. Cases which had a significant history of neurological 
disorder, head injury, or with PMI over 48 hours were excluded. The details of 
demographic and clinical data of all subjects are presented in Table 1 (Deng and Huang, 
2005). This study was approved by the Human Research Ethics Committee, University of 
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Wollongong, Australia, and complied with the NHMRC National Statement on Ethical 
Conduct in Research Involving Humans 1999. 
 
In all cases, the tissue was taken from the left-brain hemisphere of the superior temporal 
gyrus (Brodmann’s area 22). The right-brain hemispheres were fixed with formalin and 
therefore were not available for this study. Once brain tissue was collected, it was 
immediately dissected into small blocks (10 mm thick) and stored in a –80 0C freezer 
until sectioning. The brain tissue was cut into 14 µm sections using a cryostat at –17 0C 
and the sections were mounted on polysine-coated slides. All sections were stored at –20 
0C until they were thawed at room temperature prior to incubation. For each case, four 
sections were processed for total binding and two sections for non-specific binding for 
each radioligand. All sections from both schizophrenia and control cases were processed 
simultaneously to minimize experimental variance. All of the following procedures for 
autoradiography and quantitative analysis were performed while blind of diagnosis. 
 
2.2 Binding to 5-HT2A receptors 
Binding of [3H]ketanserin (88 Ci/mmol; PerkinElmerTM Life Sciences, Boston) to 5-HT2A 
receptors was performed as previously described from our group (du Bois et al., 2006). In 
brief, sections were pre-incubated in 170mM Tris-HCl buffer (pH 7.4) for 15 mins at 
room temperature (RT). Sections were then incubated for 120 mins at RT in the same 
buffer containing 4nM [3H]ketanserin in the presence (non-specific binding) or absence 
(total binding) of 2µM spiperone. After incubation, the sections were washed in ice-cold 
buffer (2х10 mins), dipped in distilled water and air dried. 
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2.3 Binding to 5-HT2C receptors 
Binding of [3H]mesulergine (84 Ci/mmol; Amersham Biosciences, Buckinghamshire) to 
5-HT2C receptors was performed as previously described from our group (du Bois et al., 
2006). In brief, sections were pre-incubated in 170mM Tris-HCl buffer (pH 7.4) for 15 
mins at RT. Sections were then incubated for 120 mins at RT in the same buffer 
containing 5nM [3H]mesulergine. Non-specific binding was determined with the addition 
of 100 nM spiperone and 1 µM mianserin. After incubation, the sections were washed in 
ice-cold buffer (2х10 mins), dipped in distilled water and air dried.  
 
 
2.4 Quantification and Statistical analysis 
Autoradiographic images were taken using a Beta Imager (BioSpace, Paris) as previously 
described (Deng and Huang, 2005). In this procedure, sections on slides were placed 
directly into a beta-imager for scanning for 3.5 h at a high-resolution setting. The levels 
of bound radioactivity in the brain sections were directly determined by counting the 
number of -particles emerging from the tissue sections. Quantitative analysis of these 
images was performed using -Image Plus (version 4; BioSpace, Paris). The radioligand 
binding signal was expressed in counts per minute per square millimetre (cpm/mm2) and 
was then converted to nCi/mg tissue equivalents (nCi/mg TE) with the use of standards. 
The specific binding was calculated by total binding minus non-specific binding. 
 
                                                                                                        Kang et al. 8 
The data were analyzed statistically using the SPSS 15.0 program (Chicago, IL). 
Comparisons between the two groups (schizophrenia and control) on radioligand binding, 
age, PMI, and brain pH were made using Student t-test. Analysis of covariance 
(ANCOVA) was performed for controlling age, PMI and brain pH in each radioligand 
binding. Pearson correlation was used to assess the relationship between binding density 
and age, brain pH, PMI, and final recorded antipsychotic drug use (FRD). To test whether 
a drug history affected the binding density, binding data between substance and non-
substance users were analysed using Mann-Whitney U test. P values less than 0.05 (2-
tailed) were considered significant. 
 
3. Results 
3.1 [3H]ketanserin and [3H]mesulergine bindings 
There were no significant differences in age, PMI, and brain pH between the 
schizophrenia and control groups (all p>0.05; Table 1). A high density of [3H]ketanserin 
binding was observed in the middle layers of the STG corresponding to layers III-V (Fig. 
1) in both schizophrenic and non-schizophrenic subjects. In contrast, there was a very 
low level of specific binding of [3H]mesulergine in the STG, which therefore limited 
further analysis of [3H]mesulergine binding in the STG. 
 
Compared to the control group, the schizophrenia group had a significant 37% decrease 
in [3H]ketanserin binding density (MeanSEM, schizophrenia 14.772.76 fmole/mg TE 
vs control 23.582.678 fmole/mg TE; F1,12=5.25, p=0.04). As shown in Table 1, half of 
the schizophrenia patients had a drug abuse history with polydrug use. The 
[3H]ketanserin binding densities in the tissues from these substance users (15.265.51 
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fmole/mg TE) were not significantly different from the non-substance users (14.272.30 
fmole/mg TE, p>0.05). There were no significant effects of age (F1,12=0.51, p=0.49), 
PMI (F1,12=0.15, p=0.71) and brain pH (F1,9=1.06, p=0.33). Furthermore, in the 
schizophrenic cases, there were no significant correlations between [3H]ketanserin 
binding density and FRD (r=-0.13, p=0.76).  
 
3.2 Correlations among 5-HT2A, muscarinic M1 and GABAA receptor bindings 
Using the same cohort of subjects, we had previously found decreased densities of 
muscarinic M1 ([3H]pirenzepine binding) and M2/M4 ([3H]AF-DX384 binding) 
receptors and increased GABAA receptor ([
3H]muscimol binding) density, but no changes 
in cannabinoid receptors, in the STG of schizophrenia (Deng and Huang, 2005, 2006; 
Deng et al., 2007). Combining our data on binding densities of 5-HT2A, muscarinic M1 
and M2/M4, and GABAA receptors from the same cohort of (both schizophrenic and 
control) subjects, there is a clear tendency for a positive correlation between 5-HT2A and 
muscarinic M1 receptor bindings (r=0.44, p=0.087, Fig. 2A), and negative correlations 
between 5-HT2A and GABAA receptor bindings (r=-0.44, p=0.087, Fig. 2B) and between 
muscarinic M1 and GABAA receptor bindings (r=-0.49, p=0.057, Fig. 2C). 
 
4. Discussion 
In this study, using [3H]ketanserin we found a significant decrease in the binding density 
of 5-HT2A receptors in the STG of the schizophrenia patients compared to the control 
subjects. In accordance with this study, a reduced expression of  5-HT2A receptor mRNA 
has also been found in the STG in schizophrenia in a previous study (Burnet et al., 1996). 
This is the first study to examine binding density of 5-HT2C receptors in human 
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postmortem brain tissue. There has also been no report on the expression of 5-HT2C 
receptor mRNA in human postmortem brain tissue.  These results suggest that the 
alterations of the 5-HT2A receptors contribute to the pathophysiology of schizophrenia in 
the STG.  
 
In line with our present findings, significant decreases in the density of [3H]ketanserin 
binding to the 5-HT2A receptor have been reported in the prefrontal cortex and 
hippocampus (Burnet et al., 1996; Dean and Hayes, 1996; Scarr et al., 2004; Matsumoto 
et al., 2005). Only one previous study examined [3H]ketanserin binding in the STG and 
did not find any change in 5-HT2A receptor density in schizophrenia, although decreases 
of  5-HT2A receptor mRNA expression were observed in the same study (Burnet et al., 
1996). It was not clear why Burnet et al. (1996) were not able to reveal the alteration of 
5-HT2A receptor density in the STG in schizophrenia.  
 
We realized the reality that it is very difficult to completely exclude the effects of 
medication on the results using postmortem tissue. In fact, all schizophrenia subjects had 
chronic illness history with antipsychotic medication, in which they normally used more 
than one (often both typical and atypical) antipsychotic drugs during medication history. 
Therefore, it is difficult to differentiate the effects of different antipsychotics on receptor 
binding in postmortem studies. Previous work has shown that chronic treatment with the 
antipsychotic drug haloperidol does not affect [3H]ketanserin binding in rats (Burnet et 
al., 1996). However, atypical antipsychotics have a high affinity to 5-HT2A receptors (for 
example: clozapine Ki=16 nM; olanzapine Ki=4 nM; risperidone Ki=0.5 nM) and 5-HT2C  
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receptors (clozapine Ki=16 nM; olanzapine Ki=23 nM; risperidone Ki= 25 nM) (DeLeon 
et al., 2004). It has been reported that chronic treatment of 5-HT2A antagonists can lead to 
a down-regulation of 5-HT2A receptors in animal studies (Van Oekelen et al., 2003). 
Previously, we have also found that chronic olanzapine treatment reduces 5-HT2A mRNA 
expression in rat brain at 2 hours after the last treatment, however, a rebound effect has 
been observed after 48 hours of drug withdrawal (Huang et al., 2006). This phenomenon 
may represent a rebound response in receptor production at the gene transcription level, 
which suggests that chronic treatment with antipsychotics (at least olanzapine) may not 
cause permanent alteration of 5-HT2A receptor mRNA expression. It worth noting that an 
increase of 5-HT2A binding in the caudate nucleus was observed in neuroleptic-naïve first 
episode schizophrenia, although there were no changes in cortical 5-HT2A receptor 
binding in same subject (Erritzoe et al., 2008), which suggests that some changes in 5-
HT2A binding possibly occurs even without antipsychotic treatment.  
 
Since the STG is involved in the pathology of schizophrenia, particularly in auditory 
hallucinations (Silbersweig et al., 1995; Kim et al., 2003; Gaser et al., 2004), abnormal 
transmission on 5-HT2A receptors may contribute to auditory hallucinations in 
schizophrenia. In fact, there is an association between polymorphism of the 5-HT2A 
receptor gene and hallucinations in schizophrenia (Ott et al., 2005). Since there is a clear 
tendency for a positive correlation between 5-HT2A and muscarinic M1 receptor bindings, 
and negative correlations between 5-HT2A and GABAA receptor bindings and between 
muscarinic M1 and GABAA receptor bindings, one possible mechanism of auditory 
hallucinations may be through interaction between 5-HT2A, acetylcholine (ACh) 
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muscarinic and GABA transmissions. Previously, Dean has proposed a role for 5-
HT/ACh muscarinic/GABA interactions in the pathology of the prefrontal cortex in 
schizophrenia, however he failed to find any correlations between 5-HT2A, M1 and 
GABAA receptors in the prefrontal cortex (Dean, 2001). 5-HT2A receptors have been 
found to be located pre-synaptically on neurons innervating cholinergic terminals in the 
cortex and modulate Ach release (Morilak et al., 1993; Cassel and Jeltsch, 1995). Since 
cortical GABAergic interneurones express both 5-HT2A and muscarinic receptors, these 
receptors may mediate inhibition of GABA release (Morilak et al., 1993; Hashimoto et 
al., 1994; Van der Zee and Luiten, 1999). Therefore, further studies on the interaction 
between 5-HT2A, muscarinic and GABA receptors are necessary for a better 
understanding of the STG pathology of schizophrenia.   
 
5. Conclusion 
This study revealed a strong [3H]ketanserin binding in the STG, but only a very weak 
[3H]mesulergine binding in the STG. A significant decrease in binding of [3H]ketanserin 
was clearly observed in schizophrenia patients in comparison with control subjects. These 
results suggested that the alterations of the 5-HT2A receptors contribute to 
pathophysiology of the STG in schizophrenia. Furthermore, there is a clear tendency for a 
positive correlation between 5-HT2A and muscarinic M1 receptor bindings, and for 
negative correlations between 5-HT2A and GABAA receptor bindings and between 
muscarinic M1 and GABAA receptor bindings. This provides a possible mechanism of 
auditory hallucinations through interactions between 5-HT2A, acetylcholine muscarinic 
and GABA transmissions in the STG in schizophrenia. 
                                                                                                        Kang et al. 13 
 
Acknowledgements 
This work was supported by a University of Wollongong URC grant to C. Deng and the 
Schizophrenia Research Institute, Australia, utilising infrastructure funding from NSW 
Health. 
                                                                                                        Kang et al. 14 
References 
Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT (2004) Meta-analysis of association 
between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. 
Schizophrenia Research 67:53-62. 
Burnet PW, Eastwood SL, Harrison PJ (1996) 5-HT1A and 5-HT2A receptor mRNAs 
and binding site densities are differentially altered in schizophrenia. 
Neuropsychopharmacology 15:442-455. 
Cassel JC, Jeltsch H (1995) Serotonergic modulation of cholinergic function in the 
central nervous system: Cognitive implications. Neuroscience 69:1-41. 
Dean B (2001) A predicted cortical serotonergic/cholinergic/GABAergic interface as a 
site of pathology in schizophrenia. Clinical & Experimental Pharmacology & 
Physiology 28:74-78. 
Dean B, Hayes W (1996) Decreased frontal cortical serotonin2A receptors in 
schizophrenia. Schizophrenia Research 21:133-139. 
DeLeon A, Patel NC, Lynn Crismon M (2004) Aripiprazole: A comprehensive review of 
its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics 26:649-
666. 
Deng C, Huang X-F (2005) Decreased density of muscarinic receptors in the superior 
temporal gyrusin schizophrenia. Journal of Neuroscience Research 81:883-890. 
Deng C, Huang X-F (2006) Increased density of GABAA receptors in the superior 
temporal gyrus in schizophrenia. Experimental Brain Research 168:587-590. 
Deng C, Han M, Huang X-F (2007) No changes in densities of cannabinoid receptors in 
the superior temporal gyrus in schizophrenia. Neuroscience Bulletin 23:341-347. 
du Bois TM, Deng C, Bell W, Huang XF (2006) Fatty acids differentially affect serotonin 
receptor and transporter binding in the rat brain. Neuroscience 139:1397-1403. 
Erritzoe D, Rasmussen H, Kristiansen KT, Frokjaer VG, Haugbol S, Pinborg L, Baare W, 
Svarer C, Madsen J, Lublin H, Knudsen GM, Glenthoj BY (2008) Cortical and 
subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode 
schizophrenic patients. Neuropsychopharmacology 33:2435-2441. 
Gaser C, Nenadic I, Volz HP, Buchel C, Sauer H (2004) Neuroanatomy of "hearing 
voices": a frontotemporal brain structural abnormality associated with auditory 
hallucinations in schizophrenia. Cerebral Cortex 14:91-96. 
Hashimoto T, Shu H, Kuriyama K (1994) Muscarinic M1 receptor mediated inhibition of 
GABA release from rat cerebral cortex. Neurochemistry International 24:389-394. 
Huang X-F, Han M, Huang X, Zavitsanou K, Deng C (2006) Olanzapine differentially 
affects 5-HT2Aand2C receptor mRNA expression in the rat brain. Behavioural 
Brain Research 171:355-362. 
Hurlemann R, Matusch A, Kuhn K-U, Berning J, Elmenhorst D, Winz O, Kolsch H, 
Zilles K, Wagner M, Maier W, Bauer A (2008) 5-HT2A receptor density is 
decreased in the at-risk mental state. Psychopharmacology 195:579-590. 
Hurlemann R, Boy C, Meyer PT, Scherk H, Wagner M, Herzog H, Coenen HH, Vogeley 
K, Falkai P, Zilles K, Maier W, Bauer A (2005) Decreased prefrontal 5-HT2A 
receptor binding in subjects at enhanced risk for schizophrenia. Anatomy & 
Embryology 210:519-523. 
                                                                                                        Kang et al. 15 
Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, Moller H-J, Muller N, Hegerl U 
(2003) Serotonergic dysfunction in schizophrenia assessed by the loudness 
dependence measure of primary auditory cortex evoked activity. Schizophrenia 
Research 64:115-124. 
Keks N, Hill C, Opeskin K, Copolov D, Dean B (1999) Psychiatric diagnosis after death: 
the problems of accurate diagnosis. In: The Use of CNS Autopsy Tissue in 
Psychiatric Research: A Practical Guide (Dean B, Hyde TM, Kleinman J, eds), pp 
19- 37. Sydney: Gordon & Breach Science Publishers. 
Kim JJ, Crespo-Facorro B, Andreasen NC, O'Leary DS, Magnotta V, Nopoulos P (2003) 
Morphology of the lateral superior temporal gyrus in neuroleptic nai;ve patients 
with schizophrenia: relationship to symptoms. Schizophrenia Research 60:173-
181. 
Li D, Duan Y, He L (2006) Association study of serotonin 2A receptor (5-HT2A) gene 
with schizophrenia and suicidal behavior using systematic meta-analysis. 
Biochemical and Biophysical Research Communications 340:1006-1015. 
Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil 
H, Lopez JF, Watson SJ (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A 
receptor mRNA expression in subjects with major depression, bipolar disorder, 
and schizophrenia.[erratum appears in Biol Psychiatry. 2004 Mar 15;55(6):660]. 
Biological Psychiatry 55:225-233. 
Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B (2005) 5-HT2A and muscarinic 
receptors in schizophrenia: a postmortem study. Neuroscience Letters 379:164-
168. 
Morilak DA, Garlow SJ, Ciaranello RD (1993) Immunocytochemical localization and 
description of neurons expressing serotonin2 receptors in the rat brain. 
Neuroscience 54:701-717. 
Nichols DE (2004) Hallucinogens. Pharmacology & Therapeutics 101:131-181. 
Ott U, Reuter M, Hennig J, Vaitl D (2005) Evidence for a common biological basis of the 
Absorption trait, hallucinogen effects, and positive symptoms: epistasis between 
5-HT2a and COMT polymorphisms. American Journal of Medical Genetics Part 
B, Neuropsychiatric Genetics: the Official Publication of the International Society 
of Psychiatric Genetics 137:29-32. 
Pralong D, Tomaskovic-Crook E, Opeskin K, Copolov D, Dean B (2000) Serotonin(2A) 
receptors are reduced in the planum temporale from subjects with schizophrenia. 
Schizophrenia Research 44:35-45. 
Saiz PA, Garcia-Portilla MP, Arango C, Morales B, Alvarez V, Coto E, Fernandez JM, 
Bascaran MT, Bousono M, Bobes J (2007) Association study of serotonin 2A 
receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with 
schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 
31:741-745. 
Scarr E, Pavey G, Copolov D, Dean B (2004) Hippocampal 5-hydroxytryptamine 
receptors: abnormalities in postmortem brain from schizophrenic subjects. 
Schizophrenia Research 71:383-392. 
Schmidt CJ, Sorensen SM, Kenne JH, Carr AA, Palfreyman MG (1995) The role of 5-
HT2A receptors in antipsychotic activity. Life Sciences 56:2209-2222. 
                                                                                                        Kang et al. 16 
Sheedy D, Garrick T, Dedova I, Hunt C, Miller R, Sundqvist N, Harper C (2008) An 
Australian Brain Bank: a critical investment with a high return! Cell & Tissue 
Banking 9:205-216. 
Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, 
McKenna P, Chua SE, Schnorr L, Johnes T, Frackowiak RSJ (1995) A functional 
neuroanatomy of hallucination in schizophrenia. Nature 378:176-179. 
Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ (2001) RNA editing of the 
5-HT(2C) receptor is reduced in schizophrenia. Molecular Psychiatry 6:373-379. 
Trichard C, Paillere-Martinot ML, Attar-Levy D, Blin J, Feline A, Martinot JL (1998) No 
serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic 
patients studied with PET. Schizophrenia Research 31:13-17. 
Tyson PJ, Roberts KH, Mortimer AM (2004) Are the cognitive effects of atypical 
antipsychotics influenced by their affinity to 5HT-2A receptors? International 
Journal of Neuroscience 114:593-611. 
Van der Zee EA, Luiten PGM (1999) Muscarinic acetylcholine receptors in the 
hippocampus, neocortex and amygdala: a review of immunocytochemical 
localization in relation to learning and memory. Progress in Neurobiology 58:409-
471. 
Van Oekelen D, Luyten WHML, Leysen JE (2003) 5-HT2A and 5-HT2C receptors and 
their atypical regulation properties. Life Sciences 72:2429-2449. 
Verga M, Macciardi F, Cohen S, Pedrini S, Smeraldi E (1997) No association between 
schizophrenia and the serotonin receptor 5HTR2a in an Italian population. 
American Journal of Medical Genetics 74:21-25. 
Verhoeff NP, Meyer JH, Kecojevic A, Hussey D, Lewis R, Tauscher J, Zipursky RB, 
Kapur S (2000) A voxel-by-voxel analysis of [18F]setoperone PET data shows no 
substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry 
Research 99:123-135. 
 
 
                                                                                                        Kang et al. 17 
 
 
 
 
 
                                                                                                        Kang et al. 18 
 
 
 
 
                             
             
Figure 1 Examples of digital autoradiograms obtained with a Beta Imager to show 
[3H]ketanserin bindings. (A) An example of postmortem brain tissue block to 
show the superior temporal gyrus (STG; enclosed in white lines) area used in 
this study;  (B) [3H]ketanserin binding in the STG of control subject; (C) 
[3H]ketanserin binding in the STG of schizophrenia subject. Scale bars: 10 mm 
for A, and 2 mm for B and C. Abbreviations: cc, corpus callosum; IG, insular 
gyrus; lf, lateral fissure; MTG, medial temporal gyrus; sts, superior temporal 
sulcus; Th, thalamus.  
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Figure 2 A, Correlation between the [3H]ketanserin and [3H]pirenzepine bindings in the 
STG (r=0.44, p=0.087). B, Correlation between the [3H]ketanserin and 
[3H]muscimol binding in the STG (r=-0.44, p=0.087). C, Correlation between the 
[3H]pirenzepine and [3H]muscimol binding in the STG (r=-0.49, p=0.057). The 
solid cycles represent the control subjects; the empty cycles are schizophrenic 
subjects with antipsychotic at death (Table 1); and the triangles are schizophrenic 
subjects without medication at death.   
 
